SCHEMBL16570158

SCHEMBL16570158

Cc1cn(S(=O)(=O)c2cccc3cccnc23)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 14/20 0.52
CCND3 P30281 11/20 0.52
CCND1 P24385 7/20 0.52
CCND2 P30279 6/20 0.52
FGFR1 P11362 2/20 0.50
FGFR2 P21802 2/20 0.50
FGFR4 P22455 2/20 0.50
FGFR3 P22607 2/20 0.50
NUAK1 O60285 1/20 0.50
CDK6 Q00534 2/20 0.49
TNK2 Q07912 1/20 0.48
CDK1 P06493 3/20 0.48
CCNB1 P14635 3/20 0.48
CCNA2 P20248 3/20 0.48
CDK2 P24941 3/20 0.48
CCNT1 O60563 2/20 0.48
CDK7 P50613 2/20 0.48
CDK9 P50750 2/20 0.48
CCNH P51946 2/20 0.48
JAK2 O60674 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570797 0.90 WEE1 (0.54) CDK4CCND3CCND1CCND2FGFR1
SCHEMBL16570214 0.88 FGFR4 (0.51) CDK4CCND3CCND1CCND2FGFR4
SCHEMBL16570589 0.85 FGFR4 (0.59) FGFR4JAK2BRD4JAK1BRD2
SCHEMBL16570263 0.83 JAK2 (0.49) CDK4CCND3CCND1CCND2FGFR1
SCHEMBL16580851 0.80 FGFR4 (0.57) FGFR4JAK2BRD4JAK1BRD2
SCHEMBL16570179 0.78 FGFR4 (0.56) FGFR4JAK2BRD4JAK1BRD2
SCHEMBL16570959 0.78 FGFR4 (0.59) CDK4CCND1FGFR4CCNA2CDK2
SCHEMBL16570057 0.78 JAK2 (0.49) FGFR4JAK2BRD4WEE1JAK1
SCHEMBL16570240 0.77 MARK3 (0.47) CDK4CCND1CDK6CDK1CCNB1
SCHEMBL16580757 0.77 RPS6KA6 (0.45) CDK4CCND3CCND1CCND2CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US disclosed
US-20150175545-A1 Preparation Method of Fluoro-Substituted Deuterated Diphenylurea SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) 2015-06-25 US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN CDK4 243/4885CCND3 1198/4885CCND1 1029/4885
US-20150175545-A1 Preparation Method of Fluoro-Substituted Deuterated Diphenylurea CCND3, UBE2D3, VDR CDK4 49/4885CCND3 1/4885CCND1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.